The Daily Mail interviews Andrew Steele, the author of Ageless: The New Science of Getting Older Without Getting Old . Steele makes a couple of key predictions in the interview: "I'd be shocked if in five years we don't have some senolytics in the clinic. It probably won't be for aging at first. It'll be for a specific disease - and maybe in 10 years, we'll use it for aging. These things are very, very near term." This market is conerned with the second of those predictions: Clinical use of senolytics in humans for the specific purpose of slowing, reversing, or preventing aging by 2033 (within 10 years of 2023). Senolytics are simply drugs whose mechanism of action is the destruction of senescent cells. Resolves YES if credible news articles or medical journals describe the successful clinical use of a new senolytic drug for anti-aging purposes outside of trials before the end date. Resolves NO otherwise. I will not be betting in this market.